Origimm received a grant from the Austrian leading public funding agency for translational research in Austria, Forschungs-Förderungs-Gesellschaft (FFG) to support the development of a vaccine against P. acnes, the bacterium that causes acne and implant-associated infections.
This significant milestone validates the innovative approach which Origimm is taking to prevent and treat common acne and hospital infections caused by P. acnes; and it underlines the significance of the medical problem that Origimm is addressing.
